EXTH-103 - Discovery and pharmacological characterization of SKL27969, a novel brain-penetrating PRMT5 inhibitor with strong antitumor activity, in glioblastoma and brain metastasis preclinical models

Friday, November 18, 2022

7:30 PM – 9:30 PM ET

Location: West/Central Hall

Poster Presenter(s)

Mijin Moon, PhD

SK Biopharmaceuticals Co., Ltd.
Seongnam, Republic of Korea

Author(s)

YS

Yongje Shin, PhD

SK Biopharmaceuticals Co.., Ltd.
Seongnam, Republic of Korea
HL

Ho Yeon Lee, PhD

SK Biopharmaceuticals Co.., Ltd.
Seongnam, Republic of Korea
BH

Beomjin Hong, PhD

SK Biopharmaceuticals Co.., Ltd.
Seongnam, Republic of Korea
JK

Jinhee Kim, PhD

SK Biopharmaceuticals Co.., Ltd.
Seongnam, Republic of Korea
JL

Jun Lee, MS

SK Biopharmaceuticals Co.., Ltd.
Seongnam, Republic of Korea
JL

Janice K. Laramy, PharmD, PhD

SK Life Science, Inc.
Paramus, United States
VV

Vijaykumar Vashi, PhD

SK Life Science, Inc.
Paramus, United States
SP

Sook-Kyung Park, PhD

SK Biopharmaceuticals Co.., Ltd.
Seongnam, Republic of Korea

Protein arginine methyltransferase 5 (PRMT5), a type II methyltransferase, regulates cellular processes such as survival, proliferation, and apoptosis by inducing symmetric arginine dimethylation of multiple cellular proteins involved in the regulation of cellular transcription and RNA splicing. Elevated tumor PRMT5 protein level has recently been correlated with poor prognosis and poor patient survival in various human cancers, including glioblastoma multiforme (GBM), lung cancer, breast cancer, and ovarian cancer. SKL27969 is a highly selective and potent PRMT5 inhibitor that is designed for brain penetration. It strongly binds to S-adenosylmethionine (SAM)-bound PRMT5/MEP50 (methylosome protein 50), leading to potent cellular symmetric dimethylarginine (SDMA) inhibition with an IC50 of 3.4 nM. Cell line panel profiling of SKL27969 revealed a broad spectrum of anti-proliferative activity in various cancer cell types, including CNS tumors, solid cancers prone to spread to brain, other solid cancers, and hematologic cancers. SKL27969 showed excellent brain exposure, with total and unbound partition coefficient (Kp and Kp_uu) values of 6.57 and 1.08, respectively, and high tumor-to-plasma ratio, which resulted in significant survival benefit in orthotopic GBM xenograft models and metastatic brain cancer models such as intracranial xenograft models of non-small cell lung cancer (NSCLC) or triple-negative breast cancer (TNBC). Administration of SKL27969 showed strong tumor growth suppression in subcutaneous xenograft models of GBM, NSCLC, or TNBC. High correlation between tumor and plasma SDMA levels after SKL27969 treatment were observed in the preclinical models. Furthermore, SKL27969 showed potentiation of DNA damage when used in combination with DNA-damaging agents, which may suggest possible benefit as a combination therapy. Given the therapeutic target potential of PRMT5 in glioblastoma and other brain metastatic cancers, and the preclinical efficacy of SKL27969, these results have enabled the initiation of Phase 1/2 open-label, multicenter dose-finding study in patients with advanced solid tumors (NCT05388435).